Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
Juan Carlos Miralles-López,Francisco Alvarez-Gutiérrez,Julio Delgado-Romero,Santiago Quirce,Jose Gregorio Soto-Campos,Ruben Andújar-Espinosa,Sheila Cabrejos-Perotti,Manuel Castilla-Martínez,Isabel Flores-Martín,Manuel José Pajarón-Fernández,José Valverde-Molina
DOI: https://doi.org/10.2147/jaa.s488764
2024-11-16
Journal of Asthma and Allergy
Abstract:Juan Carlos Miralles-López, 1, 2 Francisco J Alvarez-Gutiérrez, 3 Julio Delgado-Romero, 4 Santiago Quirce, 5, 6 Jose Gregorio Soto-Campos, 7 Ruben Andújar-Espinosa, 2, 8 Sheila Cabrejos-Perotti, 2, 9 Manuel Castilla-Martínez, 2, 10 Isabel Flores-Martín, 2, 11 Manuel José Pajarón-Fernández, 2, 12 José Valverde-Molina 2, 13, 14 1 Allergy Department, University General Hospital Reina Sofia, Murcia, Spain; 2 Severe Asthma Association of the Region of Murcia. ASGRAMUR, Murcia, Spain; 3 Medical and Surgical Unit of Respiratory Diseases, Hospital Universitario Virgen Del Rocío, Seville, Spain; 4 Allergology Clinical Management Unit, Hospital Virgen Macarena, Seville, Spain; 5 Department of Allergy, La Paz University Hospital, IdiPAZ, Madrid, Spain; 6 CIBER of Respiratory Diseases (CIBERES), Madrid, Spain; 7 Pneumology and Allergy Clinical Management Unit, University Hospital of Jerez, Jerez, Spain; 8 Pulmonology Department. H. U. Virgen de la Arrixaca, Murcia, Spain; 9 Allergy Department, University General Hospital Santa Lucia, Cartagena, Spain; 10 Pulmonology Department, University General Hospital Los Arcos, San Javier, Spain; 11 Allergy Department, Hospital Comarcal del Noroeste, Caravaca, Murcia, Spain; 12 Allergy Department, Hospital de la Vega Lorenzo Guirao, Cieza, Spain; 13 Paediatrics Department, University General Hospital Santa Lucia (Cartagena University Hospital Complex), Cartagena, Spain; 14 IMIB Biomedical Research Institute, Murcia, Spain Correspondence: Juan Carlos Miralles-López, Allergy Department, University General Hospital Reina Sofia, Murcia, Spain, Email Purpose: With the advent of biological therapies, emerging concepts regarding establishing new targets in asthma management, such as disease modification, have entered the debate among the scientific community. The definitions that form the conceptual basis of this goal need to be agreed upon. Methods: A multidisciplinary expert group was assembled as the steering committee. A systematic literature review was conducted to identify the scientific background for constructing appropriate definitions. Based on the literature review and the clinical experience of the experts, the committee built a list of statements that could be applied to establish the definition of disease modification in asthma. After that, a Delphi validation was performed to assess the appropriateness of the list of statements. The questionnaire included a total of 22 statements, divided into "Essential criteria for disease modification in asthma" (5 statements) and "Disease modification indicators and other considerations" (17 statements). Panelists used a 9-point Likert scale to measure agreement on each statement. The cut-off point for high consensus was defined as a minimum score of 7 and had to be reached by at least two-thirds of the experts. Results: A total of 192 asthma experts voted on statements anonymously. Of those, 104 (54%) were Pneumologists, 65 (34%) were allergologists, and 23 (12%) were Pediatricians. An interim analysis of round 1 data was performed. All statements reached consensus on the first round, with a median score above 7 in all cases. Conclusion: In conclusion, in this Delphi study, a large number of experts in the management of severe asthma from different specialties agreed on the clinical-functional and pathophysiological aspects to be considered in order to try to achieve disease modification. Keywords: severe asthma, disease modification, delphi process, remission In the era of biologics, asthma management has evolved substantially as the underlying mechanisms of the disease have been identified with acceptable accuracy. Therefore, treatment can be targeted in a personalized way for most patients. 1 This personalization and higher thresholds of efficacy and effectiveness have led us to introduce concepts such as remission. 2 However, in analyzing the response to biologics in asthma, we note a lack of unity in establishing which components should be included and the magnitude of improvement that can be considered sufficient to achieve that goal. 3–7 Now that future perspectives on asthma management are under debate, we would like to raise a question that goes even deeper into the foundations of the goal to be pursued: are current (and future) treatments capable of modifying the disease? This assumption arises naturally if we consider that biological treatments have, under certain circumstan -Abstract Truncated-
immunology,allergy,respiratory system